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Catecholamine-induced polymorphic ventricular tachycardia (PVT) is characterized by episodes of syncope, seizures,
or sudden death, in response to physical activity or emotional stress. Two modes of inheritance have been described:
autosomal dominant and autosomal recessive. Mutations in the ryanodine receptor 2 gene (RYR2), which encodes
a cardiac sarcoplasmic reticulum (SR) Ca2+-release channel, were recently shown to cause the autosomal dominant
form of the disease. In the present report, we describe a missense mutation in a highly conserved region of the
calsequestrin 2 gene (CASQ2) as the potential cause of the autosomal recessive form. The CASQ2 protein serves
as the major Ca2+ reservoir within the SR of cardiac myocytes and is part of a protein complex that contains the
ryanodine receptor. The mutation, which is in full segregation in seven Bedouin families affected by the disorder,
converts a negatively charged aspartic acid into a positively charged histidine, in a highly negatively charged domain,
and is likely to exert its deleterious effect by disrupting Ca2+ binding.
Catecholamine-induced polymorphic ventricular tachy-
cardia (PVT [MIM 604772]) was first described as a
distinct clinical entity by Leenhardt et al. (1995). The
disease is characterized by a reproducible form of ven-
tricular tachycardia, inducible by physical activity or cat-
echolamine infusion (fig. 1), which can rapidly deteri-
orate into ventricular fibrillation. Patients present with
recurrent syncope and/or seizures or sudden death fol-
lowing physical activity or emotional stress (Viskin and
Belhassen 1998). The disease, which appears in struc-
turally normal hearts, has a strong genetic basis, and
both autosomal dominant and recessive modes of in-
heritance have been described (Swan et al. 1999; Lahat
et al. 2001). In its autosomal dominant form, mutations
in the ryanodine receptor 2 gene (RYR2), located on
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chromosome 1q42-q43, were shown to cause the disease
(Laitinen et al. 2001; Priori et al. 2001). RYR2 encodes
a cardiac sarcoplasmic reticulum (SR) Ca2-release chan-
nel that couples the excitation of myocardial cells to their
actin/myosin contractile apparatus, by a mechanism in-
volving Ca2 release (Stokes and Wagenknecht 2000).
Recently, the spectrum of catecholamine-induced PVT
has been expanded, when Tiso et al. (2001) described
RYR2 mutations in patients with arrhythmogenic right
ventricular cardiomyopathy type 2 (ARVD2).
We have previously described an autosomal recessive
form of catecholamine-induced PVT in seven families
from a Bedouin tribe in the north of Israel (Lahat et al.
2001). Affected family members are characterized by an
early age at onset ( p years), a pen-mean SD 7 4
etrance of 100% by age 10 years, and a high mortality
rate when left untreated. The parents and carrier siblings
do not show any disease manifestations. Patients with
autosomal recessive PVT exhibit a resting bradycardia
and a mild prolongation of the QTc segment compared
with their unaffected siblings; however, they can be
clearly distinguished from patients with long QT syn-
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Figure 1 a, Baseline EKG strip (lead 3) in a patient showing normal sinus rhythm. b, EKG strip (lead 3) in the same patient during an
exercise test, showing sustained PVT.
drome on the basis of the clinical presentation, the mode
of inheritance, and the length of the QTc segment, which
is still within normal limits (Viskin and Belhassen 1998).
Patients with the autosomal recessive disease apparently
have a more malignant course, compared with those
with the autosomal dominant form, and they do not
show any pathological or clinical features of ARVD.
(Swan et al. 1999; Lahat et al. 2001).We have previously
mapped the disease-causing gene to chromosome 1p13-
p21, between the markers D1S187 and D1S534, and
have found a common haplotype in all of the carrier
chromosomes, suggesting that a single mutation is seg-
regating in these families (Lahat et al. 2001).
Through electronic screening of DNA clones from the
linkage interval, we have identified two microsatel-
lite CA repeats, DJ108CA (clone RP11-114K10) and
DJ776CA (clone AL139345), amplified with the primer
pairs 5′-GTTCAGGGACACACTGCTCCTC-3′ and 5′-
CAAAGTCCTTGAATTCTTACAC-3′, and 5′-CAATA-
ACTTGTATTGTATAATG-3′ and 5′-GATATTTTGAT-
ATCCATATAC-3′, respectively. Recombination and
haplotype analysis with these markers refined the linkage
interval to 8 Mb (fig. 2a). Currently, 46 known tran-
scripts map to this interval (Human Genome Working
Draft Web site; see the Weizman Institute of Science
Crown Human Genome Center Web site for a list of
genes).
The recent implication of RYR2 in the autosomal
dominant form of catecholamine-induced PVT (Laitinen
et al. 2001; Priori et al. 2001) focused our attention on
another gene involved in the same pathway of SR cal-
cium control, located in the linkage interval calsequestrin
2 (CASQ2). CASQ2 (MIM 114251) is composed of 11
exons and encodes a 399–amino acid protein. This gene
is known to be the only calsequestrin expressed in car-
diac muscle, whereas skeletal muscle expresses CASQ2
as well as its homologue (91% identity), calsequestrin
1 (CASQ1 [MIM 114250]) (Yano and Zarain-Herzberg
1994). CASQ2 was previously mapped, by fluorescence
in situ hybridization, to human chromosome 1p11-
p13.3 (Otsu et al. 1993), but its accurate genomic dis-
position remained unknown. Searching the most recent
version of genomic databases, we were able to identify
two genomic clones that contained all 11 exons that
constitute the CASQ2 cDNA (fig. 2b) (Ensembl Genome
Server).
Sequencing of the CASQ2 exons revealed a GrC non-
synonymous substitution (fig. 3a) at nucleotide 1038
(exon 9), resulting in a change from aspartic acid to
histidine at position 307 of the protein. No other se-
quence variations were noted in the coding region of this
gene. The D307H mutation creates a BamHI restriction
site in the mutated sequence. A full segregation of the
mutation was observed in all of the families, and an
example of one family is shown in figure 3b. Screening
of 350 control subjects, including 250 Jewish, 50 Bed-
ouin, and 50 Israeli Arabs, identified only the wild-type
form. Alignment of sequences of two cardiac and three
muscle calsequestrin genes from different vertebrates, as
well as two calsequestrin genes from invertebrates,
shows that the sequence variation that we have found
occurs in a highly conserved amino acid, both in ver-
tebrates and in invertebrates (fig. 4a).
The calsequestrin 2 protein, which serves as the major
Ca2 reservoir within the SR of cardiac myocytes, has
an ability to bind extremely large numbers of Ca2 cat-
ions. The rabbit CASQ1 can bind and release 40–50
Ca2 ions per protein molecule at each contraction-re-
laxation cycle (Yano and Zarain-Herzberg 1994). This
is explained by the existence of 160 highly conserved
Figure 2 a, Physical map of the PVT locus. Landmark genes are shown as red boxes with their HUGO nomenclature symbols. Microsatellite markers are indicated by arrows (f) pointing to
their exact position on the genomic bar map. Black denotes the boundaries of the linkage interval defined elsewhere (Lahat et al. 2001), and green indicates markers within the linkage interval defined
in the present study. b, Expanded view of a 75-kb segment, showing the genomic organization of the CASQ2 interval. The interval is covered by two genomic clones that have 5-kb overlap. AL449264
contains the first four exons, and AL450389 contains the other seven exons, depicted by blue boxes. The lengths of the exons are shown below the boxes, and those of the introns are shown above
the line. The translation-initiation site and the stop codon are indicated.
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Figure 3 a, Sequence chromatograms from a patient (M/M), a
noncarrier (WT/WT), and a carrier (WT/M). There is a GrC substi-
tution at nucleotide 1038 in exon 9, converting aspartic acid to his-
tidine at codon 307. b, BamHI restriction analysis of the D307H
mutation in one of the Bedouin families. The 258-bp PCR product of
exon 9 is cleaved in the carrier chromosome to yield 131-bp and 127-
bp products that comigrate on the agarose gel. MW p molecular
weight marker.
anionic Asp and Glu residues in a protein of ∼400 amino
acids (Yano and Zarain-Herzberg 1994). Figure 4b
shows a three-dimensional model of human CASQ2 that
we have constructed using rabbit skeletal muscle calse-
questrin structure as a template (Wang et al. 1998). The
predicted structure of CASQ2, like that determined ex-
perimentally for CASQ1, is composed of three thiore-
doxin-like domains (MacLennan and Reithmeier 1998;
Wang et al. 1998), which enclose an interdomain space
with a highly hydrophilic surface lining and a strong net
negative charge. This acidic core has been proposed to
be stabilized by binding of Ca2 cations (Wang et al.
1998) and is likely to play an important role in the
chelation and sequestration of Ca2 ions. Residue 307,
which harbors the mutation, protrudes into the inter-
domain space (fig. 4c), and its undergoing a change from
a negatively charged aspartic acid to a positively charged
histidine may disrupt the normal chelation function.
In cardiac excitation-contraction coupling, the SR
plays an essential role in the regulation of the cytosolic
free Ca2 concentrations. Three major stages have been
identified: (1) Ca2 uptake from the cytosol into the SR
lumen, resulting in muscle relaxation; (2) Ca2 storage
in the SR lumen; and (3) Ca2 release from the SR into
the cytosol, resulting in muscle contraction (Carafoli
1987). Stimulation of voltage-sensitive L-type calcium
channels (dihydropyridine) located in the sarcolemma
permits the entry of extra small amounts of Ca2, which
activate the ryanodine receptors. This leads to the release
of large amounts of Ca2 from calsequestrin into the
cytosol, initiating contractility (Puglisi et al. 1996). Two
additional proteins involved in the Ca2 cascade release,
junctin and triadin, interact directly in the junctional SR
membrane and stabilize a quaternary protein complex
that anchors calsequestrin to the ryanodine receptor and
that may be required for normal operation of Ca2 re-
lease (Zhang et al. 1997). Studies of isolated human
myocardial preparations suggested that impaired Ca2
handling by the SR is an important subcellular mecha-
nism contributing to the depressed contractility in heart
failure (Hasenfuss et al. 1997). In these studies,CASQ2-
expression levels were unaltered, suggesting specific and
rigid regulation of this protein in cardiac tissue.
Recently, transgenic mice were formed that exhibited
a 10-fold overexpression of CASQ2. These mice devel-
oped severe cardiac hypertrophy and heart failure, with
a twofold increase in heart mass and cell size, in addition
to a resting bradycardia, a prolonged electrocardio-
graphic QTc interval, and an increased incidence of sud-
den death attributed to arrhythmia (Jones et al. 1998;
Knollmann et al. 2000). The last three features are sim-
ilar to those found in our patients, whereas cardiac hy-
pertrophy and heart failure are absent. Electrophysio-
logical studies of these mice suggested that at least some
of the pathological manifestations are caused by an im-
pairment in the Ca2-release process.
The detailed mechanism whereby the D307H muta-
tion induces PVT remains to be elucidated. Calcium re-
lease from the SR is regulated by at least three factors:
the magnitude of the triggering Ca2 influx, the state of
the ryanodine receptors, and the Ca2 content within the
SR (Volders et al. 2000). Increased intracellular Ca2
(“Ca2 overload”) can trigger both early and delayed
afterdepolarizations, which are oscillations of the
membrane potential that occur during the plateau/re-
polarization phase of the action potential or after its
completion, respectively (Rubart and Zipes 2001). Af-
terdepolarizations have been implicated as the patho-
physiological basis for different clinical arrhythmias, in-
cluding bidirectional ventricular tachycardia and PVT
(Priori and Corr 1990). Thus, these experiments may
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Figure 4 a, Multiple alignment of a segment of the human CASQ2 protein with the corresponding segments in some of its homologues.
The sequences were selected using a BLASTP (Altschul et al. 1997; NCBI BLAST Home Page) search of human CASQ2 against the nonredundant
protein database. Multiple alignment of the entire protein length was performed by the ClustalW program, using the default parameters (Higgins
et al. 1996). Acidic amino acids are shown in red, basic amino acids in blue, and yellow denotes all other amino acids. The top sequence is
for the mutated human CASQ2, and the arrow (f) indicates the D307H mutated position. The GenBank accession numbers of the aligned
proteins are as follows: human cardiac calsequestrin (CASQ2), O14958; mouse cardiac calsequestrin (CASQ2), O09161; human skeletal muscle
calsequestrin (CASQ1), P31415; chicken skeletal muscle calsequestrin (CASQ1), P19204; frog skeletal muscle calsequestrin (CASQ1), P31231;
Caenorhabditis elegans calsequestrin, Q20203; and Drosophila melanogaster disulfide isomerase, giF1709616. This is the Drosophila protein
showing highest protein similarity to human CASQ2, and both share a thiorodoxin-like structural motif. b, Ribbon drawing of human CASQ2
three-dimensional homology model. The D307 amino acid is shown in orange. The model was calculated using “homology” and “discovery”
modules of Biosym/MSI. The protein termini were omitted for the modeling calculation, leaving a G22-to-L366 amino acid core. The default
parameters were used to generate a loop (E345 to P353). Energy minimization was performed using steepest-descent (100 iterations) and
conjugate-gradient (1,000 iterations) algorithms. c, A closer look at the mutant position domain. The basic and acidic amino acids are shown,
in blue and red, respectively, as “balls and sticks.” The top model is of the wild-type protein (D307), and the bottom model is of the mutant
protein (H307). The substitute position is shown in orange (for D307) and green (for H307). The histidine in the mutant form appears to
disrupt a band of negative amino acids and could thus upset the protein’s charge balance.
suggest that an intracellular “Ca2 overload” is the trig-
gering force initiating the arrhythmias. The mutated
CASQ2 may directly increase the Ca2 content within
the SR, alter the function of the ryanodine receptor to
which it is connected, or impair the Ca2 release process
in a way analogous to the transgenic mice model. Cat-
echolamines induce intracellular overload of Ca2 by
a variety of mechanisms (Rona 1985; Marban and
O’Rourke 1995). In the patients with PVT, catechola-
mines may further increase intracellular Ca2 levels and
trigger PVT.
In a setting in which all of the carrier chromosomes
are derived from a common ancestor, any genetic variant
linked to the actual disease-causing gene would be ex-
pected to segregate with the disease in all of the studied
families. An amino acid substitution like the one we have
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found can represent a silent polymorphism; however,
several lines of evidence presented above implicate the
D307H substitution as the cause of catecholamine-in-
duced PVT in our families. First, this amino acid change
was not found in any of 700 chromosomes from normal
control individuals. Second, this change occurred in an
amino acid that is highly conserved throughout evolu-
tion. Third, molecular modeling shows that this muta-
tion is associated with a change in the electrostatic prop-
erties of the protein that may affect its Ca2-binding
capacity. Fourth, mutations in RYR2, which takes part
in the same biochemical pathway as CASQ2 and forms
a protein complex with it, causes a phenotype very sim-
ilar to the phenotype presented in this study. Future iden-
tification of more mutations in CASQ2 in other families
with this disorder, as well as the creation of a mouse
knock-in model, will provide additional evidence that
this is indeed the disease-causing gene.
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